Abstract Chronic vascular inflammation is regarded as a crucial aspect of cardiovascular disease. However, the elicitors of this inflammatory response in the vessel wall are currently not well understood. Excessive amounts of cholesterol, an abundant and fundamental lipid molecule in mammalian cells, can initiate the development and progression of atherosclerosis. Accumulation of cholesterol in early atherosclerotic lesions results in the formation of macrophage foam cells, and crystalline cholesterol is found as a characteristic of advanced atherosclerotic plaques. Cholesterol crystals can activate the NLRP3 inflammasome, a multimolecular signaling complex of the innate immune system, resulting in caspase-1 mediated activation and secretion of proinflammatory interleukin-1 family cytokines. Furthermore, crystalline cholesterol is believed to induce plaque rupture by physical disruption of the fibrous cap covering atherosclerotic lesions. Here we review the effect of cholesterol deposition and crystallization on inflammatory responses in cardiovascular diseases.
Introduction
Inflammation results from immune responses toward stimuli that occur during microbial infection and tissue damage. The innate immune system is an evolutionarily conserved defense system that relies on germline-encoded patternrecognition receptors (PRRs) expressed on innate immune cells and on other host cells. These PRRs detect unique microbial substances, so called pathogen-associated molecular patterns (PAMPs), and endogenous molecules released from damaged cells, named damage-associated molecular patterns (DAMPs). Activation of these receptors initiates signaling cascades that lead to the transcription of proinflammatory cytokines, chemokines, type I interferons (IFNs), antimicrobial peptides, and proteins involved in the modulation of PRR signaling. The resulting inflammatory response is crucial to the clearance of infectious agents and damaged cells, for tissue repair, and for initiation of adaptive immunity. Unresolved, chronic inflammation, however, can be harmful to the host and can initiate several pathologies [1] .
Since the discovery that PRRs can also be involved in the recognition of endogenous self-molecules that appear during cell death or tissue injury, many stimuli causing sterile inflammation have been discovered. Most of these stimuli comprise such self-molecules as endogenous nucleic acids, heat shock proteins, extracellular matrix components, or purine metabolites, for example ATP, which are usually located in specific cellular compartments but become accessible to immune cells after damage or death of the cell [2] . NLRP3, a member of the NOD-like receptor (NLR) family of PRRs, has been linked to the inflammatory response to a variety of aggregated or crystalline materials of endogenous or environmental origin. These substances induce the formation of the NLRP3 inflammasome, an intracellular multimolecular protein complex comprising the adaptor molecule apoptosis-associated speck-like protein containing a CARD (ASC) and pro-caspase-1. Upon its recruitment to ASC, autocatalytic activation of pro-caspase-1 occurs and results in the proteolytic activation and release of proinflammatory interleukin (IL)-1β family cytokines [3] . It has been demonstrated that the NLRP3 inflammasome can contribute to chronic crystal-induced inflammatory diseases, for example gout, pseudogout, asbestosis, silicosis, and, more recently, atherosclerosis.
Although much has been learned about the involvement of the NLRP3 inflammasome in crystal-mediated diseases, a unifying molecular mechanism leading to activation of this multimolecular protein complex has yet to be discovered. Because the NLRP3 inflammasome can be activated by a large number of diverse initiators, an indirect activation mechanism is likely [4, 5, 6••, 7•, 8] .
Here, we will discuss the inflammatory potential of crystalline cholesterol and its involvement in cardiovascular disease.
Physical Characteristics of Cholesterol
Cholesterol is an essential lipid in vertebrates that is derived from nutrition and from endogenous biosynthesis. As an ubiquitous component of all cellular membranes it is crucially involved in membrane structure and function and it is important for maintaining membrane permeability and cell signaling. In addition, cholesterol metabolites, for example bile acids, oxysterols, vitamin D and steroid hormones, have essential physiological functions.
Free cholesterol has very low solubility in aqueous environments and lipoproteins serve as cholesterol carriers for cholesterol transport in the bloodstream. Cells obtain most exogenous cholesterol from circulating lipoproteins via LDL receptor-mediated endocytosis. LDL-derived cholesterol is incorporated into cellular membranes and excess free cholesterol becomes esterified by acyl-coenzyme A:cholesterol acyltransferase (ACAT) which enables cholesterol esters to be stored inside cells in so-called lipid droplets. Stored cholesterol esters can be converted back into cholesterol by the cellular enzyme cholesterol ester hydrolase (CEH). Mammalian cells cannot degrade cholesterol and hence elimination of excess cholesterol is of particular importance for maintaining cellular cholesterol homeostasis. Efflux of free cholesterol from cells is mainly mediated by high-density lipoprotein (HDL) consisting of apolipoproteins A-I and A-II (apoA-I and apoA-II), phospholipids, cholesterol, and cholesterol esters. HDL acquires cholesterol from cells either via passive diffusion, because of a cholesterol gradient between the cell surface and tangent HDL particles, or via an apolipoprotein-mediated transport process involving ABC transporters in the plasma membrane. In particular, ABCA1 transfers cholesterol and phospholipids to lipid-poor apoA-I, resulting in the generation of nascent HDL particles. In macrophages, a second transporter, ABCG1, has been found to be involved in cholesterol efflux to mature HDL. HDL particles are responsible for retrograde cholesterol transport (RCT) to the liver and steroidogenic tissues, where HDL-derived cholesterol becomes metabolized or prepared for excretion [9] .
Although cholesterol biosynthesis, transport, and metabolism are tightly controlled, defects in these pathways or disruption of cholesterol homeostasis can result in various pathologies. Atherosclerosis, for instance, is characterized by accumulation of lipids and immune cells in the arterial intima. In the 1970s Small et al. analyzed the physical properties of cholesterol, found monohydrate cholesterol crystals at 37°C, and emphasized the presence of extracellular crystalline cholesterol in advanced atherosclerotic lesions [10] . Furthermore, in-vitro studies with lipid-laden macrophage foam cells revealed that the formation of cholesterol monohydrate crystals also occurs intracellularly on accumulation of free cholesterol inside the cells [11, 12] . Taken together, these findings indicated that the accumulation of free, unesterified cholesterol can lead to deposition of cholesterol crystals in vessel walls.
Cholesterol Crystal Interaction with Serum Proteins
In the early 1970s it was reported that HDL has the potential to remove cholesterol from cells and atherosclerotic tissues. However, it was also noted that turnover of cholesterol in atherosclerosis is relatively slow, which was thought to be a consequence of ineffective phagocytosis and metabolism of the crystalline cholesterol in the arterial walls. Nevertheless, direct interactions between HDL and cholesterol crystals were also analyzed in vitro. This interaction between HDL and crystalline cholesterol resulted in the de-novo formation of liposomes on the crystal surface and solubilization of cholesterol crystals. In addition, effective clearance of cholesterol crystals from HDL-incubated human atherosclerotic lesions was demonstrated [13, 14] . Furthermore, an in-vivo model in rats showed the capacity of oxysterols to potently solubilize cholesterol crystals from subcutaneous implants. Hence, oxysterols, by enhancing the solubility of cholesterol, could increase cholesterol clearance from tissues by favoring cholesterol incorporation into HDL particles, thus reducing the atherogenic potential of cholesterol [15] . These studies demonstrated the involvement of HDL in preventing accumulation of cholesterol inside cells and in the arterial subendothelial space. In addition, these data indicated that HDL may directly target crystalline cholesterol for dissolution. Complement is another plasma protein that interacts with cholesterol crystals leading to activation of the complement system. These studies were the first to propose that crystalline cholesterol was directly involved in activation of the immune system and progression of atherosclerosis. High concentrations of cholesterolwhen provided as cholesterol-loaded lipid A liposomes -can induce antibodies against cholesterol crystals, demonstrating that cholesterol can, indeed, be immunogenic [16] . It is also possible that in patients with IgG antibodies against crystalline cholesterol the classical complement pathway can be activated by cholesterol crystals [17] . These experiments provided evidence for the immunostimulatory potential of cholesterol, especially in the crystalline state, and its potential involvement in cardiovascular disease.
Cholesterol Crystals and Inflammation
Cholesterol crystals have also been implicated in diseases other than atherosclerosis. For instance, crystalline cholesterol can be found in cholecystolithiasis. In this disorder, a biochemical imbalance of lipids and bile salts in the bile can mediate precipitation of cholesterol leading to gallstones and gall bladder inflammation. Indeed, cholesterol monohydrate crystals form in supersaturated bile and are regarded as a prerequisite for the development of cholesterol gallstones [18] .
Chronic apical periodontitis, another cholesterol-crystal related disease, has some similarities to atherosclerosis. Apical periodontitis develops in response to endodontic microbial infection of the root canal system. Conventional treatment involves elimination of the pathogens followed by orthograde root filling to prevent reinfection, but in rare cases this treatment is not sufficient and periapical accumulation of cholesterol crystals causes a non-resolving chronic inflammation. Although accumulation of cholesterol crystals in these lesions was, for a long time, regarded as a common histopathological feature of apical periodontitis, their effect in mediating chronic inflammation was only deciphered much later. An experimental study with guinea pigs revealed that cholesterol crystal implants were densely surrounded by macrophages and multinucleate giant cells, suggesting that cholesterol crystals are detected by the host immune system. Although these cells were unable to eliminate the cholesterol crystals, induction of an inflammatory response against this crystalline material was observed [19] . Furthermore, an in-vitro study demonstrated that macrophages exposed to crystalline cholesterol release osteotropic cytokines, for example IL-1α [20] . Both the inflammatory response and the bone-resorbing activity were implicated in the impaired healing upon endodontic treatment and the development of this chronic inflammatory disease.
A feature shared by chronic apical periodontitis and cardiovascular disease is the presence of so-called cholesterol crystal clefts that result from the deposition of large cholesterol crystals which are dissolved during histological sample preparation. This analogy suggested that similar inflammatory responses to accumulated crystalline cholesterol can occur in arterial vessel walls.
Evidence of the involvement of crystalline cholesterol in cardiovascular inflammation came from studies on ACAT as a potential drug target. It was hypothesized that preventing the formation of macrophage foam cells, a characteristic of early atherosclerotic lesions, could slow the progression of atherosclerosis and circumvent atherosclerosis plaque development. Thus, chemical ACAT inhibitors were tested in clinical trials with advanced atherosclerosis patients. Against expectations, however, ACAT inhibition did not reduce but rather increased atheroma development [21, 22] . Moreover, experiments with ACAT-1 knockout mice revealed that ACAT-1 deficiency does not prevent the development of atherosclerotic lesions but results in the accumulation of extracellular crystalline cholesterol accompanied by a marked inflammatory response [23] . These studies indicated that cholesterol phase transition to its crystalline form is linked to inflammation in tissues. Nevertheless, the involvement of cholesterol crystals in cardiovascular inflammation had largely been disregarded because crystalline cholesterol was primarily found in the later stages of atherosclerotic plaque development and thus their appearance was thought to be the consequence of disease progression.
Cholesterol Crystal Formation in Atherosclerosis
Atherosclerosis is a progressive disease starting with accumulation of lipids, lipoproteins, and immune cells in the arterial wall. Disease progression results in narrowing of the arterial lumen because of continuous plaque growth. Advanced atherosclerotic lesions have a lipid-rich necrotic core that may be covered by a so-called fibrous cap composed of extracellular matrix components and smooth muscle cells. Thinning of this fibrous cap in advanced disease is a critical event, because it reduces plaque stability. This favors lesion rupture and luminal thrombosis which can initiate the acute clinical events myocardial infarction and stroke [24] .
It is well recognized that cardiovascular inflammation is of central importance in atherosclerosis. Although some viral pathogens and bacterial pathogens have been associated with the development of human atherosclerosis, a study using germ-free mice indicated that the inflammation driving the atherosclerotic process is independent of an infectious organism and suggested that atherogenesis can be initiated by endogenous molecules [25] . One suspected endogenous initiator was cholesterol, which was known to accumulate in atherosclerotic plaques in the form of intracellular cholesterol esters in foam cells or as intra-and extracellular crystalline material.
Abela and colleagues investigated the involvement of crystalline cholesterol in advanced atherosclerotic lesions. They observed that crystallization of cholesterol led to volume expansion and could result in sharp-edged cholesterol crystals with the potential to penetrate biological membranes [26] . Thus, cholesterol crystallization was assumed to be an inducer of plaque rupture, because the crystals had the potential to perforate the outer layers of atherosclerotic plaques (Fig. 1) . Indeed, scanning electron microscopy of human coronary arteries provided evidence for this hypothesis [27] and revealed cholesterol crystals perforating the arterial intima in patients that had died from acute coronary syndrome, but not in those who had severe atherosclerosis but no acute cardiac events [28] . These studies were the first to imply that cholesterol crystals can initiate plaque disruption and vascular injury.
Crystalline cholesterol can be found in all stages of atherogenesis and is present in early atherosclerotic lesions [6••, 10] . Two independent studies showed that cholesterol crystals can be phagocytosed by murine or human macrophages. In phagocytic cells that engulf abundant amounts of cholesterol crystals lysosomal damage is induced, which results in activation of the NLRP3 inflammasome with subsequent activation of caspase-1 and activation and secretion of IL-1β family cytokines [ (Fig. 1) . IL-1β family cytokines have long been described as potent pro-atherogenic cytokines and their appearance and activation correlated with disease severity [29] . Bonemarrow transplantation from mice deficient in NLRP3 into irradiated atherosclerosis-prone LDL-receptor (LDLR) knockout mice resulted in reduced lesion development upon receiving a high-cholesterol diet [6••] . Together with the findings that IL-1β-deficiency in an apolipoprotein E (ApoE) knockout atherosclerosis model attenuates disease progression [30] , these results suggested that cholesterol crystal-induced NLRP3 inflammasome activation and subsequent IL-1β production can drive atherogenesis. Another study on ApoE-deficient mice lacking NLRP3 inflammasome components did not, however, result in differences in atherogenesis [31] . The reasons for the difference in outcome are not entirely clear. ApoE-deficient mice are known to have a more severe atherogenic phenotype than LDLRdeficient mice [32] . In addition, the ApoE-deficient mice used in the latter study [31] were fed a much stronger atherogenic diet (about eightfold more cholesterol) for a longer time than the LDLR-deficient mice in the other study [6••] . It is known that several redundant mechanisms contribute to atherosclerosis development and thus experimental conditions could have a large effect on the gene-dose effect. A recent study investigating the role of autophagy in atherosclerosis provided further evidence for the importance of inflammasome activation on cardiovascular disease progression [33•] . In macrophage-specific ATG5-null (ATG5-mϕKO) mice, a common mouse model for autophagy deficiency, enlarged atherosclerotic plaques with increased cholesterol crystal content were observed. It was, furthermore, demonstrated that cholesterol crystal-mediated inflammasome activation was higher in macrophages deficient in autophagy, and resulted in an enhanced proatherogenic IL-1β response. Collectively, these studies [6••, 7•, 33 •] indicate that the inflammatory response caused by cholesterol crystalinduced NLRP3 inflammasome activation is one of the forces driving atherosclerosis development and progression.
Potential Therapeutic Approaches Based on Cholesterol Crystal-Induced Inflammation Despite progress in disease prevention and advances in the medical and surgical treatment of atherosclerosis during recent decades, cardiovascular disease remains the leading cause of mortality worldwide. Therefore, novel therapeutic strategies to treat atherosclerosis and associated diseases are urgently needed. The findings that cholesterol crystals and the subsequently induced inflammation are critical in the early and late atherosclerotic process [6••, 34] , indicate that reducing plaque cholesterol crystal content or blocking the inflammasome pathway could reduce the initiation or progression of atherosclerosis.
Prevention of cholesterol crystal formation might be achieved by lowering the plaque cholesterol load and enhancing retrograde cholesterol transport, for instance by raising plasma levels of HDL or by increasing the expression of ABC transporters to promote HDL function. Because low concentrations of HDL in the blood are among the most prominent risk factors for cardiovascular disease [35] , intense efforts are in progress to develop methods to increase HDL levels. In particular, cholesterol ester transfer protein (CETP) is regarded as a potential drug target because it can significantly increase HDL concentrations while reducing LDL levels [36] . However, disappointing results were obtained from initial clinical trials evaluating the effects of the CETP inhibitor torcetrapib. Despite beneficial changes in lipoprotein levels, major cardiac events and overall mortality were significantly increased, presumably because of off-target effects, for example elevated blood pressure, leading to premature termination of the ILLUMINATE study. Nevertheless, CETP remains a promising drug target, because another CETP inhibitor (anacetrapib) and a CETP modulator (dalcetrapib) do not have the unfavorable off-target effects of torcetrapib [37] . However, a phase III trial assessing the effectiveness of dalcetrapib (dal-OUTCOMES) in preventing atherosclerosis-related morbidity has recently been halted because of futility [38] . Another clinical trial, REVEAL, which tests the effectiveness of anacetrapib, is still ongoing.
Other therapeutic strategies for cardiovascular disease involve reduction of vessel wall inflammation. As mentioned above, proinflammatory IL-1 cytokines are crucially involved in atherogenesis. Under physiological conditions the proinflammatory activity of IL-1 cytokines is controlled by a naturally occurring IL-1 receptor agonist (IL-1Ra). This structural homologue of IL-1 competes with IL-1 cytokines for binding to the IL-1 receptor (IL-1R) without inducing its activation [39] . The proatherogenic character of IL-1 cytokines has been demonstrated in a variety of animal studies. A deficiency of IL-1β in an atherosclerosis mouse model reduced atherosclerosis progression [30] whereas IL-1Ra-deficiency promoted atherosclerotic lesion development [40] . Furthermore, overexpression IL-1Ra [41] or administration of recombinant IL-1Ra [42] reduced the size of atherosclerotic lesions. Finally, a clinical study using canakinumab, a human monoclonal neutralizing IL-1β antibody is in progress. The canakinumab anti-inflammatory thrombosis outcomes study (CANTOS) will evaluate the effect of IL-1β inhibition on major cardiac events in patients with preexisting coronary artery disease [43•] . IL-1β could, however, also have protective effects in advanced atherosclerosis, because it can mediate pro-fibrotic tissue responses. Indeed, it was recently demonstrated that atherosclerotic plaques of IL-1R-deficient ApoE knockout mice placed on a high-cholesterol diet had features of plaque instability in advanced lesions, for example reduced plaque smooth muscle cells and plaque collagen content, and increased intraplaque hemorrhage [44] . These effects could be beneficial in maintaining stable plaques. Nevertheless, it is also well established that atherogenesis and lesion size are dramatically reduced in mice with altered IL-1 signaling, and the benefits of anti-IL-1β are likely to outweigh potential risks.
Although there is hope for the success of these clinical trials, further therapeutic approaches might be directly targeted at the elicitors of vascular inflammation. In particular, potential agents mediating the dissolution of cholesterol crystals and thus promoting the efflux of excess cholesterol from atherosclerotic lesions might have beneficial effects. Furthermore, better understanding of the molecular mechanisms resulting in NLRP3 inflammasome activation by cholesterol crystals might reveal novel potential drug targets for treatment of atherosclerosis.
Conclusions
The immune system recognizes when endogenous molecules, for example uric acid or cholesterol, change their physical state from soluble to crystalline. These mechanisms have probably evolved to recognize sterile tissue damage. After tissue damage, uric acid and, potentially, other molecules are misplaced from intracellular pools to the extracellular environment and the capacity of cells to control the amount of free cholesterol diminishes. Immune cells in the tissues, for example tissue macrophages and dendritic cells, can recognize these danger signals and alert other immune cells via the production of cytokines of the IL-1β family. These mechanisms of recognition of sterile tissue damage can, however, also lead to chronic inflammatory responses if the danger signals appear chronically or are not efficiently cleared, for example those observed in the arteries of hypercholesteremic individuals or the joints of hyperuricemic patients. It is likely that pharmacological prevention of cholesterol crystallization in the early stages of disease or reduction of cholesterol crystal plaque content in the advanced stages might reduce atherogenesis. Therefore, cholesterol crystals themselves might be a new target of approaches to treat atherosclerosis.
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